Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease
- 17 December 2009
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 39 (9), 2177-2187
- https://doi.org/10.1039/b919237a
Abstract
Neurodegenerative diseases like Alzheimer's and Parkinson's disease are associated with elevated levels of iron, copper, and zinc and consequentially high levels of oxidative stress. Given the multifactorial nature of these diseases, it is becoming evident that the next generation of therapies must have multiple functions to combat multiple mechanisms of disease progression. Metal-chelating agents provide one such function as an intervention for ameliorating metal-associated damage in degenerative diseases. Targeting chelators to adjust localized metal imbalances in the brain, however, presents significant challenges. In this perspective, we focus on some noteworthy advances in the area of multifunctional metal chelators as potential therapeutic agents for neurodegenerative diseases. In addition to metal chelating ability, these agents also contain features designed to improve their uptake across the blood–brain barrier, increase their selectivity for metals in damage-prone environments, increase antioxidant capabilities, lower Aβ peptide aggregation, or inhibit disease-associated enzymes such as monoamine oxidase and acetylcholinesterase.This publication has 87 references indexed in Scilit:
- Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer diseaseNeuroscience Letters, 2009
- Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxideJournal of Inorganic Biochemistry, 2008
- Novel Near-Infrared Fluorescent Integrin-Targeted DFO AnalogueBioconjugate Chemistry, 2007
- Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1Journal of Neurochemistry, 2006
- Oxidative stress and neurodegeneration: where are we now?Journal of Neurochemistry, 2006
- Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)Chemical Reviews, 2006
- The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategyBritish Journal of Pharmacology, 2005
- Iron, brain ageing and neurodegenerative disordersNature Reviews Neuroscience, 2004
- Neurodegenerative diseases and oxidative stressNature Reviews Drug Discovery, 2004
- Protection against Oxidative Damage by Iron Chelators: Effect of Lipophilic Analogues and Prodrugs of N,N‘-Bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N‘-diacetic Acid (OR10141)Journal of Medicinal Chemistry, 2000